Literature DB >> 21844883

Return of inactivated whole-virus vaccine for superior efficacy.

Yoichi Furuya1.   

Abstract

The swine, influenza, H1N1 outbreak in 2009 highlighted the inadequacy of the currently used antibody-based vaccine strategies as a preventive measure for combating influenza pandemics. The ultimate goal for successful control of newly arising influenza outbreaks is to design a single-shot vaccine that will provide long-lasting immunity against all strains of influenza A virus. A large amount of data from animal studies has indicated that the cross-reactive cytotoxic T (Tc) cell response against conserved influenza virus epitopes may be the key immune response needed for a universal influenza vaccine. However, decades of research have shown that the development of safe T-cell-based vaccines for influenza is not an easy task. Here, I discuss the overlooked but potentially highly advantageous inactivation method, namely, γ-ray irradiation, as a mean to reach the Holy Grail of influenza vaccinology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21844883     DOI: 10.1038/icb.2011.70

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  28 in total

Review 1.  Laser vaccine adjuvants. History, progress, and potential.

Authors:  Satoshi Kashiwagi; Timothy Brauns; Jeffrey Gelfand; Mark C Poznansky
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Dose sparing and the lack of a dose-response relationship with an influenza vaccine in adult and elderly patients - a randomized, double-blind clinical trial.

Authors:  Zoltan Vajo; Gergely Balaton; Peter Vajo; Laszlo Kalabay; Adam Erdman; Peter Torzsa
Journal:  Br J Clin Pharmacol       Date:  2017-04-11       Impact factor: 4.335

3.  Characterization of humoral and cellular immune features of gamma-irradiated influenza vaccine.

Authors:  Fengjia Chen; Ho Seong Seo; Hyun Jung Ji; Eunji Yang; Jung Ah Choi; Jae Seung Yang; Manki Song; Seung Hyun Han; Sangyong Lim; Jae Hyang Lim; Ki Bum Ahn
Journal:  Hum Vaccin Immunother       Date:  2020-07-09       Impact factor: 3.452

Review 4.  Seasonal influenza vaccine in immunocompromised persons.

Authors:  Mohammad Bosaeed; Deepali Kumar
Journal:  Hum Vaccin Immunother       Date:  2018-03-21       Impact factor: 3.452

Review 5.  Development of cross-protective influenza a vaccines based on cellular responses.

Authors:  Peter Christiaan Soema; Elly van Riet; Gideon Kersten; Jean-Pierre Amorij
Journal:  Front Immunol       Date:  2015-05-15       Impact factor: 7.561

6.  Ebolavirus nucleoprotein C-termini potently attract single domain antibodies enabling monoclonal affinity reagent sandwich assay (MARSA) formulation.

Authors:  Laura J Sherwood; Andrew Hayhurst
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

7.  Near-infrared laser adjuvant for influenza vaccine.

Authors:  Satoshi Kashiwagi; Jianping Yuan; Benjamin Forbes; Mathew L Hibert; Eugene L Q Lee; Laura Whicher; Calum Goudie; Yuan Yang; Tao Chen; Beth Edelblute; Brian Collette; Laurel Edington; James Trussler; Jean Nezivar; Pierre Leblanc; Roderick Bronson; Kosuke Tsukada; Makoto Suematsu; Jeffrey Dover; Timothy Brauns; Jeffrey Gelfand; Mark C Poznansky
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

8.  Membrane-bound IL-12 and IL-23 serve as potent mucosal adjuvants when co-presented on whole inactivated influenza vaccines.

Authors:  Tila Khan; Connie L Heffron; Kevin P High; Paul C Roberts
Journal:  Virol J       Date:  2014-05-03       Impact factor: 4.099

9.  A heat-inactivated H7N3 vaccine induces cross-reactive cellular immunity in HLA-A2.1 transgenic mice.

Authors:  Giuseppina Di Mario; Bruno Garulli; Ester Sciaraffia; Marzia Facchini; Isabella Donatelli; Maria R Castrucci
Journal:  Virol J       Date:  2016-03-31       Impact factor: 4.099

10.  Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge.

Authors:  Diletta Magini; Cinzia Giovani; Simona Mangiavacchi; Silvia Maccari; Raffaella Cecchi; Jeffrey B Ulmer; Ennio De Gregorio; Andrew J Geall; Michela Brazzoli; Sylvie Bertholet
Journal:  PLoS One       Date:  2016-08-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.